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Introduction. Lung cancer remains one of the most prevalent forms of cancer, with approximately 20 000 new cases reported every
year in Spain, and 18000 deaths due to this disease. Radiotherapy, with or without other therapeutic modalities, is an effective
treatment. Our objective was to report on the use of radiotherapy for lung cancer and its variability in our region during 2007.
Objective. To report on the use of radiotherapy for lung cancer, its variability in our region, and to compare our results with the
previous study done in 2004 (VARA-I) in our region and with other published data.
Methods. We reviewed the clinical records and radiotherapy treatment sheets of all patients undergoing radiotherapy for lung
cancer among patients diagnosed during 2007 in the 12 public hospitals in Andalusia. Data were gathered on hospital type,
patient type, radiotherapy treatment characteristics, histological type, and tumor stage.
Results. 3051 patientswere diagnosedwith lung cancer, but only 610 patients underwent initial radiotherapy (19.9%).Most patients
had stage III squamous cell lung cancer with good performance status and were treated with radical therapy. The majority of
patients with non-small and small cell lung cancer were treated with concomitant chemo-radiotherapy. The most common
regimen for patients treated with palliative intent was 30Gy (10 fractions×3Gy per fraction). The total irradiation rate was 19.6%
with signiﬁcant differences among provinces (range, 8.5–25.6%; p<0.001). These differences were signiﬁcantly correlated with
the geographical distribution of radiation oncologists (r=0.78; p=0.02). Our results were similar to other published data and
previous study VARA-I.
Conclusion. There is still excessive variability in the application of radiotherapy for lung cancer in our setting.
http://dx.doi.org/10.1016/j.rpor.2013.03.312
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Introduction. A simple clinical tool able to predict the probability of radio-induceddysphagia on inoperable lung cancer patients has
been designed. Its applicability may suppose the preventive therapeutic measures on patients with high probability to develop
it.
Objectives. Compare the real radio-induced acute dysphagia degree with the one obtained according to the MAASTRO Clinic
prediction model.
Methods. Retrospectively, the clinical data of 25 lung cancer patients in stages I–III treated with conformal radiotherapy with
radical intention, exclusively or associated with sequential or concomitant chemotherapy were collected. With this data (age,
gender, WHO performance status, mean esophageal dose (MED), maximum esophageal dose (MAXED) and overall treatment
time (OTT), the MAASTRO Clinic radio-induced acute dysphagia (RAD) prediction model (for G2 and G3) was applied and it was
compared with the real toxicity (CTV v3.0). The data was analyzed with the statistical program SPSS v.15.
Results. The sample media age was of 65 years. 19 patients (76%) were of male sex. The 84% (21) correspond to NSCLC and 16%
(4) to SCLC. The 88% (22) were stage III. Regarding to the treatment modality: 13(52%) received concomitant chemotherapy-
radiotherapy, while 10 (40%) sequential radiotherapy. Concerning to the RAD: 3(12%), 7(28%) and 13 (52%) correspond to G0, G1
and G2 respectively. There was not G3. The real toxicity was compared to the one obtained according to the predictive model,
nevertheless, no statistically signiﬁcant correlation was obtained.
Conclusions. In our series there is not statistically correlation between the real RAD and the one obtained applying the mentioned
predictive model. However, there is a clear tendency to reach it, especially, in relation to the II degree when it surpasses the 50%
of probability of observing it. We will continue recollecting data in order to expand the sample size and be able to demonstrate
the stated relationship.
http://dx.doi.org/10.1016/j.rpor.2013.03.313
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Introduction. Small Cell LungCancer (SCLC)makesupabout 15%of all lung cancer. This histology grouphave thepoorest prognostic
at this cancer site because its high tendency to local and regional recurrence and, mainly, distant metastases. Role of radiation
treatment exclusively or combined with chemotherapy, is uncertain.
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Objectives. To compare patient outcomes and primary tumor behaviours in patients with SCLC that received radiation treat-
ment in tumor primary site and chemotherapy and other group did not and only received systemic treatment (antineoplastic
chemotherapy).
Patients and methods. This is a retrospective cohort study between April 2007 and December 2011, with a minimum follow up of
12 months. 37 consecutive patients diagnosed with SCLC were treated in our Radiation Oncology Unit in this period. 19 patients
received only loco-regional treatment, that include primary tumor and lymph node drainage. Prophylactic cranial irradiation like
single treatment was given to 15 patients and only three both treatment modalities (loco-regional lung irradiation plus PCI).
Results. Survival rates in patients that primary tumor were treated had a mean survival of 19 months and in no primary treated
group had 13 months, a mean difference of 6 months Conﬁdence Interval 95% (0.26–11.74) and p=0.041. Cumulative incidence
of distant metastasis in group with treatment of primary tumor was 0.578; CI 95% (0.36–0.76) and 0.88; CI 95% (0.67–0.96) in arm
without this option the difference, p<0.03. Relative Risk 1.53 CI 95% (1.01–2.32) and Relative Risk Reduction −0.53 CI 95% (−1.33;
−0.01) and NNT=−3. Finally, cumulative incidence of local recurrence in primary treatment group was 0.26; 26% and 0.44; 44%
in no primary treatment group, showing a p=0.25. Almost, it shows an Absolute Risk Reduction of −0.18 CI 95% (−0.44, +0.11),
NNT −6 CI 95% (−2, +8), Relative Risk 1.68 CI 95% (0.67–4.2).
Conclusions. There are signiﬁcant differences about distant metastases incidence and mean survival time in patients that received
radiation treatment in primary tumor vs no treatment group.
http://dx.doi.org/10.1016/j.rpor.2013.03.314
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To evaluate the safety and efﬁcacy of EGFR TKIs in combination with RT in the treatment of bone metastasis in patients with
NSCLC.
Methods. We reviewed the data from patients with NSCLC EIV, that received treatment with TKIs (Erlotinib or Geﬁtinib) and RT for
bone metastasis between 2009 and 2012. For clinical response we used the visual analog scale (VAE) to evaluate the pain control,
comparing the preRT value with the 3 months postRT value. A complete clinical response(CR) was considered with a VAE of 0-1
after RT, a partial response(PR) if the initial value was the same or if it decreased, and no response if it increased. To evaluate the
radiological response a comparison was made before and 3 months postRT by the radiologist.
Results. Overall 20 patients were analysed, with a total of 39 localizations receiving RT. RT to a total dose of 8–30Gy in 1–10
fractions was used. A positive EGFR mutation status was achieved in seven patients, and negative or no information in the rest.
Eight concomitant treatments (RT and TKIs) were applied. The RT and TKIs clinical response rate at three months was CR in 75%
(6) and a PR in 25% (1). The radiological response was informed stable or PR in 87.5% (7). One progressed in both ﬁelds Toxicity
from concomitant RT and TKIs included 3 patients with G1 rash, one with G2 rash, and esophagitis G1 in one patient.
Conclusions. Our ﬁndings suggest that RT and TKIs therapy for bone metastases were feasible, safe and effective.
http://dx.doi.org/10.1016/j.rpor.2013.03.315
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Purpose/objective(s). For lung cancer stereotactic body radiation therapy (SBRT), the use of a highly conformal dose delivery tech-
nique becomes essential for minimizing the dose to organs at risk (OAR), while simultaneously enabling dose escalation. There
are different new techniques to achieve this goal. Two of them are intensity modulated radiation therapy (IMRT) with helical
tomotherapy (HT) and volumetric modulated arc therapy (VMAT) with RapidArc. The aim is to perform a dosimetric comparison
of both for SBRT in early stage non-small cell lung cancer (NSCLC).
Materials/methods. Three patients with stage I NSCLC with peripherally located lesions completed RapidArc SBRT using 6 MV
photons with 2 half-arc plan (180◦). All ﬁnal dose calculations were performed using the Acuros algorithm. For comparative
purposes, a new treatment plan was generated using IMRT with HT for each patient. For HT plans, the 2.5 cm ﬁeld size was
chosen with a pitch of 0.287 that resulted in a modulation factor of 1.7. The SBRT schedule was 60Gy in 8 fractions. The resulting
PTV coverage, OAR doses and treatment delivery times were assessed.
Results. HT plans achieved a slightly superior D98%, D95% and D90% to PTV. For both lungs excluding the PTV, V20, V13, V10, V5
and mean lung dose (MLD) was lower with RapidArc, as well as V33 for chest wall. For other OAR both plans were comparable.
Delivery of a 7.5Gy-fraction required an average of 13.2 min (HT) and 4 min (RapidArc).
Conclusions. HT and RapidArc plans showed good target coverage for lung SBRT. RapidArc plan also minimized the dose to normal
lung tissue and chest wall with the advantage of a shorter treatment delivery times.
http://dx.doi.org/10.1016/j.rpor.2013.03.316
